Jalpa Doshi PhD, Research Assistant, Professor, General Internal Medicine, University of Pennsylvania, Philadelphia, PA USA
Bonnie Handke RN, Director, Health Policy and Planning, Medtronic, Inc, Neuromodulation, Shoreview, MN, USA
Jennifer Stephens PharmD, Clinical Director& Partner, Pharmerit North America LLC, Bethesda, MD, USA

Gisselle Gallego PhD, Research Fellow, Centre for Health Economics Research and Evaluation (CHERE) University of Sydney, Australia
Wim Goettsch PhD, Consultant Pharmacoeconomics Dutch Health Insurance Board, Diemen, Netherland
Seema Haider MSc, Director, Pfizer Inc, Global HE/OR,Groton, CT, USA
Franz Hessel MD, MPH, Senior Manager, Sanofi-Aventis, Managed Markets / HEOR, Berlin, Germany
Tove Holm-Larsen MSc, University of Denmark, Denmark
Deborah Lubeck PhD, Vice President Icon Clinical Research, Half Moon Bay, CA, USA
John O'Donnell PhD, Regional Director, Astra-Zeneca, New York, NY, USA
Dan Ollendorf MPH, Chief Review Officer, Institute for Clinical and Economic Review, Boston, MA, USA
Carlos Gouveia Pinto PhD, Associate Professor of Health Economics, Technical University of Lisbon, Lisbon, Portugal

1. To describe current methods used globally in health technology assessment and health care reimbursement policies.
2. To describe issues with current methods used globally in health technology assessment and health care reimbursement policies.
3. To develop a priority list for the development of good research practices for use in health technology assessment and health care reimbursement policies.

• Most Common Methodologies for Drugs by Stage

Survey to assess current methods used globally in health technology assessment and health care reimbursement